Boston Institute of Biotechnology

BIB at BPI East Congratulations to Ravi Chari for presenting his work with Stephanie Delzell, Zhaoling Jiang, Liyan CHEN, Matthew Sousa, and Justin Lin on optimizing chemical cell lysis conditions to determine protein titer at BPI East. The team conducted a study of different chemical lysis parameters with the goal of optimizing those conditions to achieve total protein recovery from analytical samples. While no significant improvement in recovery using increased amounts of Bugbuster and Lysonase was observed, the findings revealed that centrifugation during chemical lysis caused protein loss. This was likely due to detergent-induced protein instability, highlighting the need for tailored lysis protocols for specific proteins. Proud of our team’s dedication to advancing bioprocessing standards! #BPIEast #ProteinRecovery #Biotechnology #BostonInstituteOfBiotechnology ? To read the full poster, visit this link on our website below:

BIB at BPI East Congratulations to Grace Tan for presenting her work with Salvador Vazquez Reyes, Natalie Kay, Kady Oakley, Shawn Nie, Dogan Ornek on endotoxin control in process development at BPI East! Their poster showcased innovative strategies for managing endotoxin levels from upstream bacterial fermentation to downstream purification. Proud of our team’s dedication to advancing bioprocessing standards! #BPIEast #EndotoxinControl #Biotechnology #BostonInstituteOfBiotechnology #Bioprocessing To read the full poster, visit this link on our website below:

Day 1 BIO EU Recap The BIB team kicked off BIO-Europe yesterday, connecting with biotech leaders and exploring new opportunities to drive innovation in drug development. We're thrilled to showcase our expertise in various areas of drug development and discuss potential collaborations to accelerate therapeutic pipelines.? If we haven’t met yet, come by Booth 168—we’d love to connect! #BIOEurope #Biotechnology #BIB #Innovation #DrugDevelopment #LifeSciences?

Are you attending BIO-Europe in Sweden??? ? Our business development team invites you to visit our booth to learn how our full range of services can support your projects, from early development to commercial manufacturing. Join us to discuss how we can work together to advance the future of biotechnology. Event Details: Date: November 4 - 6? Location: Stockholm, Sweeden? Booth:?#168?

Monoclonal Antibodies Are Transforming the Future of Medicine Monoclonal antibodies (mAbs) are transforming the landscape of modern medicine, driven by their ability to target disease pathways with remarkable precision. According to Vision Research Reports, the global monoclonal antibodies market is projected to grow at a CAGR of 11.07% over the next decade, reaching $679.03 billion by 2033. The versatility of mAbs extends across multiple therapeutic areas, including oncology, autoimmune disorders, and infectious diseases. Their specificity allows for precise targeting of disease-associated proteins, minimizing off-target effects and paving the way for safer, more effective treatments. In the rapidly evolving field of biotechnology, advancements in antibody engineering have led to the development of next-generation modalities, such as bispecific antibodies and antibody-drug conjugates, further expanding their application. Additionally, the trend towards personalized medicine is shaping the future of mAb therapies, with treatments increasingly tailored to individual patient profiles. This shift highlights the growing importance of mAbs in the development of targeted therapies that can address specific molecular markers in various diseases. The global expansion of the monoclonal antibodies market, particularly in regions like Asia-Pacific, combined with the rise of biosimilars and innovative manufacturing approaches, reflects a dynamic and competitive landscape. As the market continues to evolve, it underscores the pivotal role mAbs will play in addressing some of the most pressing healthcare challenges of our time. For more information visit this link: https://lnkd.in/dCtAP2_U #Biotechnology #MonoclonalAntibodies #PrecisionMedicine #TargetedTherapies #Biopharmaceuticals #Innovation #AntibodyEngineering #HealthcareTransformation?

The future of antibody-drug conjugates (ADCs) in cancer treatment!? ? ADCs represent a cutting-edge approach in targeted cancer therapy, combining the specificity of monoclonal antibodies with potent cytotoxic agents. This innovative technology allows for precise delivery of cancer-fighting drugs directly to tumor cells, potentially improving efficacy while reducing side effects.? ? Key advantages of ADCs:? Targeted delivery to cancer cells? Reduced systemic toxicity? Potential for improved therapeutic outcomes? ? With 13 FDA-approved ADCs as of November 2023, including 6 for solid tumors, this field is rapidly advancing. ADCs have shown impressive results in clinical trials for various cancer types, including breast, ovarian, urothelial, and lung cancers.? ? By focusing on enhancing antibody stability, increasing drug-antibody ratios, and reducing immunogenicity, BIB continues to work towards developing novel ADC solutions with clients. As ADCs continue to demonstrate efficacy in various tumor types, we're committed to refining this technology and setting new benchmarks in therapeutic delivery systems.? ? For more information visit this link: https://lnkd.in/dtiyG_YV? ? #CancerResearch #Biotechnology #ADCs #TargetedTherapy #Innovation?#Biospace

Microbial Identification: Advancing Therapeutic Development As we advance deeper into the biotech and pharma landscapes, the critical role of microbial identification continues to gain momentum. The recent report on the?Microbial Identification Market?projects an impressive growth trajectory, reaching?$8.1 billion by 2033. This expansion highlights the increasing reliance on precision tools to identify and understand microbial populations that impact therapeutic pipelines. For companies with a stake in biologics, cell and gene therapies, or microbiome-based therapeutics, this evolving market offers not just opportunities but a necessity to integrate advanced microbial identification technologies into R&D and production workflows. These tools are essential for: Ensuring product purity?and safety throughout development.? Optimizing manufacturing processes?by identifying contaminants and enhancing strain productivity.? Supporting regulatory compliance?in line with FDA and EMA standards for microbial control. As biotech continues to embrace complex biologics, from monoclonal antibodies to gene-editing platforms, the demand for robust microbial identification systems will only intensify. Pharma leaders must stay ahead by leveraging these technologies to minimize risk, ensure efficacy, and drive?faster, more accurate therapeutic development. For more information visit this link: https://lnkd.in/dD9R7ubT BioSpace #Biotechnology #Pharmaceuticals #TherapeuticDevelopment #Biologics #Microbiome

We are live at CPHI Milan!? ? Our team invites you to visit our booth to explore how our comprehensive services can support your projects, from early-stage development to commercial manufacturing. Let’s discuss how we can collaborate to drive the future of biotech forward! Event Details:? ? October 8 - 10? ? Location: Milan, Italy? ? Booth: 18D9? ? ?#CPHI #Biotechnology #Innovation #Pharma #BIB

September Highlights - what a month it’s been for us in biotech! Sept 24: We proudly sponsored BiotechTuesday, with over 300 attendees, kicking off with a panel featuring our leaders showcasing innovations from molecule to market: - Laura Maugeri: Epic-CHO High Producing CLD Platform - Nida Sayed Zubairy: Optimization of AAV Vector Production - Ravi Chari: Residual Host Cell DNA Characterization - Chi Ming Yu: Ultra-Large-Scale Biomanufacturing - Abbie Watts: MC Sept 23: Honored to be finalists in two categories at Biotech Week Boston "BWB" Awards: 1. Deal of the Year: recognizing the companies involved in forming a transformative business partnership that are projects to move the industry forward, making a positive impact on patient lives. 2. Boston Highlight: recognizing a standout life-sciences organization based in the Boston area that has made a significant contribution to the biopharmaceutical industry over the past year. Sept 23-26: Showcased at BioProcess International with poster presentations, panels, and our booth. To note: Pitchai Sangan BIB's Associate Director of CLD shared his insights on Accelerating CLD and FIH studies. Sept 10: Our CEO received Frost & Sullivan's Global CDMO Technology Leadership Award for Biologics for our contributions to biologics manufacturing. Read the full article here: https://lnkd.in/ehyqb4ij Follow our LinkedIn page to stay up to date on our events and research, and contact us via our website, we would love to collaborate and support innovations in Biotech! www.bostonbib.com #BiotechInnovation #LifeSciences #Biologics #CDMO #HealthcareLeadership #BiotechWeekBoston #AAV #CellLineDevelopment #Biomanufacturing #BiotechEvents #Pharma #HealthcareInnovation #BiotechNews #MoleculeToMarket

An Exciting Announcement from the Boston Institute of Biotechnology! ? We’re gearing up for CPhI next week and can’t wait to connect with industry leaders at Booth 18D9 in Milan. ? Why You Should Visit Us: - Discover the world's first ultra-large bioreactor and its transformative capabilities. -Learn about the first 30kL scale mammalian cell line and the largest microbial CDMO capacity in the world! - Engage in discussions about our comprehensive services in gene therapy, cell therapy, and beyond. - Explore partnership opportunities that can drive innovation in biotechnology. ? This is your chance to connect with our experts and learn how we can help turn your ideas into life-saving medicines. Don’t miss out—let’s shape the future of biotech together! ? #CPhI2024 #Biotechnology #CDMO #Innovation #BostonInstituteOfBiotechnology